Download MendeleyDiscovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.
Li, Z., Wang, X., Eksterowicz, J., Gribble, M.W., Alba, G.Q., Ayres, M., Carlson, T.J., Chen, A., Chen, X., Cho, R., Connors, R.V., DeGraffenreid, M., Deignan, J.T., Duquette, J., Fan, P., Fisher, B., Fu, J., Huard, J.N., Kaizerman, J., Keegan, K.S., Li, C., Li, K., Li, Y., Liang, L., Liu, W., Lively, S.E., Lo, M.C., Ma, J., McMinn, D.L., Mihalic, J.T., Modi, K., Ngo, R., Pattabiraman, K., Piper, D.E., Queva, C., Ragains, M.L., Suchomel, J., Thibault, S., Walker, N., Wang, X., Wang, Z., Wanska, M., Wehn, P.M., Weidner, M.F., Zhang, A.J., Zhao, X., Kamb, A., Wickramasinghe, D., Dai, K., McGee, L.R., Medina, J.C.(2014) J Med Chem 57: 3430-3449
- PubMed: 24641103
- DOI: https://doi.org/10.1021/jm500118j
- Primary Citation of Related Structures:
4TTH - PubMed Abstract:
We describe the structural optimization of a lead compound 1 that exhibits dual inhibitory activities against FLT3 and CDK4. A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivatives was synthesized, and SAR analysis, using cell-based assays, led to the discovery of 28 (AMG 925), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date. Compound 28 inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb(+)) and U937 (FLT3(WT)) and induced cell death in MOLM13 (FLT3(ITD)) and even in MOLM13 (FLT3(ITD, D835Y)), which exhibits resistance to a number of FLT3 inhibitors currently under clinical development. At well-tolerated doses, compound 28 leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.
Organizational Affiliation:
Departments of †Therapeutic Discovery, ‡Oncology Research, §Pharmaceutics, and ∥Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.
